Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Détails
ID Serval
serval:BIB_E223D6B7A947
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Périodique
Scandinavian journal of gastroenterology
ISSN
1502-7708 (Electronic)
ISSN-L
0036-5521
Statut éditorial
Publié
Date de publication
12/2016
Peer-reviewed
Oui
Volume
51
Numéro
12
Pages
1482-1488
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The cause of anti-TNF-induced psoriasis is still unknown.
We aimed to evaluate if the appearance of psoriasis under anti-TNF therapy is associated with anti-TNF antibody levels and TNF-antagonist trough levels.
In this case-control study we identified 23 patients (21 with Crohn's disease [CD], two with ulcerative colitis [UC]) who developed psoriasis under infliximab (IFX, n = 20), adalimumab (ADA, n = 2), and certolizumab pegol (CZP, n= 1) and compared them regarding the anti-TNF-antagonist antibody levels with 85 IBD patients (72 with CD, 13 with UC) on anti-TNF therapy without psoriasis.
Median disease duration was not different between the two groups (7 years in the group with psoriasis under TNF-antagonists vs. 10 years in the control group, p = 0.072). No patient from the psoriasis group had antibodies against TNF-antagonists compared to 10.6% in the control group (p = 0.103). No difference was found in IFX trough levels in the group of patients with psoriasis compared to the control group (2.6 μg/mL [IQR 0.9-5.5] vs. 3.4 μg/mL [IQR 1.4-8.1], p = 0.573). TNF-antagonist therapy could be continued in 91.3% of patients with TNF-antagonist related psoriasis and most patients responded to topical therapies.
Anti-TNF-induced psoriasis seems to be independent of anti-TNF antibodies and trough levels. Interruption of Anti-TNF therapy is rarely necessary.
We aimed to evaluate if the appearance of psoriasis under anti-TNF therapy is associated with anti-TNF antibody levels and TNF-antagonist trough levels.
In this case-control study we identified 23 patients (21 with Crohn's disease [CD], two with ulcerative colitis [UC]) who developed psoriasis under infliximab (IFX, n = 20), adalimumab (ADA, n = 2), and certolizumab pegol (CZP, n= 1) and compared them regarding the anti-TNF-antagonist antibody levels with 85 IBD patients (72 with CD, 13 with UC) on anti-TNF therapy without psoriasis.
Median disease duration was not different between the two groups (7 years in the group with psoriasis under TNF-antagonists vs. 10 years in the control group, p = 0.072). No patient from the psoriasis group had antibodies against TNF-antagonists compared to 10.6% in the control group (p = 0.103). No difference was found in IFX trough levels in the group of patients with psoriasis compared to the control group (2.6 μg/mL [IQR 0.9-5.5] vs. 3.4 μg/mL [IQR 1.4-8.1], p = 0.573). TNF-antagonist therapy could be continued in 91.3% of patients with TNF-antagonist related psoriasis and most patients responded to topical therapies.
Anti-TNF-induced psoriasis seems to be independent of anti-TNF antibodies and trough levels. Interruption of Anti-TNF therapy is rarely necessary.
Mots-clé
Adalimumab/adverse effects, Adalimumab/therapeutic use, Adolescent, Adult, Case-Control Studies, Certolizumab Pegol/adverse effects, Certolizumab Pegol/therapeutic use, Female, Humans, Inflammatory Bowel Diseases/complications, Inflammatory Bowel Diseases/drug therapy, Infliximab/adverse effects, Infliximab/therapeutic use, Logistic Models, Male, Multivariate Analysis, Psoriasis/etiology, Switzerland, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Young Adult, Crohn’s disease, Psoriasis, adalimumab, certolizumab pegol, inflammatory bowel disease, infliximab, ulcerative colitis
Pubmed
Web of science
Création de la notice
16/09/2016 17:46
Dernière modification de la notice
20/08/2019 16:06
Données d'usage
